Evidence map›Paper›PMID 36852737›Full record

ArticleeLife2023

Single cell preparations of

Ekansh Mittal, Andrew T Roth, Anushree Seth, Srikanth Singamaneni, Wandy Beatty, Jennifer A Philips

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. HowVaccines · 2026
    Review
  3. Review
  4. Future Research Directions on Mycobacterium tuberculosis Proteins.Advances in experimental medicine and biology · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Molecular biology of the cell · 2025
    Article
  9. Zinc-limitedInfection and immunity · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Progress of single-cell sequencing technology in immunotherapy for tuberculosis.Frontiers in cellular and infection microbiology · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Formation ofMethodsX · 2024
    Article
  19. Article
  20. The chosen few:Frontiers in immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ekansh Mittal *Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, United States.ORCID 0000-0001-9034-033X
Andrew T Roth *Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St Louis, United States.ORCID 0000-0003-4239-7926
Anushree SethDepartment of Mechanical Engineering and Materials Science, Institute of Materials Science and Engineering, Washington University in St. Louis, St Louis, United States.
Srikanth SingamaneniDepartment of Mechanical Engineering and Materials Science, Institute of Materials Science and Engineering, Washington University in St. Louis, St Louis, United States.
Wandy BeattyDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, United States.
Jennifer A PhilipsDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, United States.ORCID 0000-0002-9476-0240
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
PRINCIPLES IN PULMONARY RESEARCHT32HL007317 · NHLBI · WASHINGTON UNIVERSITY · PI Steven Brody, Michael J Holtzman · 1985 to 2026
$16.1M
Mechanisms of Innate Immune Evasion by Mycobacterium TuberculosisR01AI130454 · NIAID · WASHINGTON UNIVERSITY · PI JENNIFER A PHILIPS · 2017 to 2026
$5.9M
THE ROLE OF ESCRT IN MACROPHAGE RESISTANCE TO MYCOBACTERIAR01AI087682 · NIAID · WASHINGTON UNIVERSITY · PI PHILIPS, JENNIFER A · 2011 to 2022
$4.9M
Adaptive Treatment for Adolescent Cannabis Use DisordersR01DA030454 · NIDA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KAMINER, YIFRAH · 2011 to 2015
$2.0M
METAL-ORGANIC FRAMEWORK AS PROTECTIVE COATING FOR CANCER BIOSPECIMEN PRESERVATIONR21CA236652 · NCI · WASHINGTON UNIVERSITY · PI MORRISSEY, JEREMIAH J, SINGAMANENI, SRIKANTH · 2019 to 2021
$705k
NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NCI NIH HHS R21 CA236652NCI NIH HHS R21CA236652NHLBI NIH HHS T32 HL007317NHLBI NIH HHS T32 HL007317-37NIAID NIH HHS R01 AI087682NIAID NIH HHS R01 AI130454NIAID NIH HHS R01 AI30454NIDA NIH HHS R01 DA030454
6 · The paper itself

Abstract

For decades, investigators have studied the interaction of

Indexed as

Mycobacterium tuberculosisTuberculosisAnimalsHost-Pathogen InteractionsMacrophagesMicePhagosomesTumor Necrosis Factor-alphaTumor Necrosis Factor-alphahost-pathogen interactionsinfectious diseasemacrophagemicrobiologymousemycobacterium tuberculosis

Identifiers

PMID36852737
PMCPMC9998084
OpenAlexW4322616775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.